About STAT-Dx
STAT-Dx is a Healthcare company based in Barcelona (Spain) founded in 2010 by Jordi Carrera, and was acquired by Qiagen in January 2018. Syndromic testing systems for respiratory and gastrointestinal pathogens are developed. STAT-Dx has raised $34.32 million across 1 funding round from investors including Qiagen and Gilde Healthcare. Its chief executive, as recorded, is Jordi Carrera. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Diversified.
Company details
STAT-Dx was founded in 2010 in Barcelona, Spain, within the molecular diagnostics sector. Proprietary technologies, including the DiagCORE Cartridge and DiagCore Analyser, are utilized for point-of-care syndromic testing of bacterial and viral pathogens. The cartridge integrates reagents for cell lysis, nucleic acid purification, qPCR amplification, and hybridization. Operations focus on two test panels targeting respiratory and gastrointestinal infections.
- Headquarters Barcelona, Spain
- Founders Jordi Carrera
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website stat-dx.com
- Social LinkedIn X
- Acquired by Qiagen (Jan 2018)
Funding Insights of STAT-Dx
STAT-Dx has successfully raised a total of $34.32M through 1 strategic funding round. The most recent funding activity was a Series A round of $34.32 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $34.32M
- Total Rounds 1
- Last Round Series A — $34.32M
- First Round $34.32M
(Jun 2016)
- Investors Count 1
All 1 funding rounds of STAT-Dx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $34.32M | Series A | – | Gilde Healthcare | – |
2 investors in total: 2 institutional.
Investors in STAT-Dx
STAT-Dx has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Qiagen and Gilde Healthcare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture captial firm focused on healthcare sectors | gildehealthcare.com | Cambridge, United States | ||
Products and reagents for molecular diagnostic assays are supplied. | 1984 | qiagen.com | Hilden, Germany |
Investor details for STAT-Dx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of STAT-Dx
1 people are tracked at STAT-Dx (1 in leadership).
| Name | Role | Group |
|---|---|---|
Jordi Carrera | Founder & CEO | Leadership |
Complete people profiles for STAT-Dx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of STAT-Dx
3 dated milestones of STAT-Dx across 8 years, from founding to its latest funding, stage changes and deals.
- Founded STAT-Dx is founded.
- Funding First funding round of $34.3M.
- Exit Acquired by Qiagen.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Stat-Dx
Complete news archive for STAT-Dx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about STAT-Dx
STAT-Dx was founded in 2010 and raised its 1st funding round 6 years after it was founded.
STAT-Dx is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Jordi Carrera is the CEO of STAT-Dx, as recorded in our data. They have also founded this company.
STAT-Dx is a funded company, having raised a total of $34.32M across 1 funding round to date. The company's 1st funding round was a Series A of $34.32M, raised on Jun 2016.
STAT-Dx was founded in 2010 in Barcelona, Spain, within the molecular diagnostics sector. Proprietary technologies, including the DiagCORE Cartridge and DiagCore Analyser, are utilized for point-of-care syndromic testing of bacterial and viral pathogens. The cartridge integrates reagents for cell lysis, nucleic acid purification, qPCR amplification, and hybridization. Operations focus on two test panels targeting respiratory and gastrointestinal infections.
STAT-Dx has 2 investors. Key investors include Qiagen, and Gilde Healthcare.
Yes. STAT-Dx was acquired by Qiagen in January 2018.